286 related articles for article (PubMed ID: 25981178)
1. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.
Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493
[TBL] [Abstract][Full Text] [Related]
3. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients.
Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J
Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959
[TBL] [Abstract][Full Text] [Related]
4. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis.
Zhang C; Zhang Y; Cai J; Chen M; Song L
Pharmacogenomics J; 2017 Jan; 17(1):92-97. PubMed ID: 26503818
[TBL] [Abstract][Full Text] [Related]
5. Metabolic monitoring and management among clozapine users.
Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D
Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
[TBL] [Abstract][Full Text] [Related]
8. Nurse-led lifestyle intervention in a cohort of schizophrenia patients treated with clozapine.
Mallorquí A; Oliveira C; Rios J; Isla-Pera MP; Gil-Badenes J; Amoretti S; Bernardo M; Vieta E; Parellada E; Garriga M; García-Rizo C
Arch Psychiatr Nurs; 2023 Oct; 46():51-57. PubMed ID: 37813503
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of the metabolic syndrome among patients receiving clozapine.
Lamberti JS; Olson D; Crilly JF; Olivares T; Williams GC; Tu X; Tang W; Wiener K; Dvorin S; Dietz MB
Am J Psychiatry; 2006 Jul; 163(7):1273-6. PubMed ID: 16816234
[TBL] [Abstract][Full Text] [Related]
10. Dyspepsia and constipation in patients with schizophrenia spectrum disorders.
Virtanen T; Eskelinen S; Sailas E; Suvisaari J
Nord J Psychiatry; 2017 Jan; 71(1):48-54. PubMed ID: 27564411
[TBL] [Abstract][Full Text] [Related]
11. Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.
Yang L; Chen J; Li Y; Wang Y; Liang S; Shi Y; Shi S; Xu Y
World J Biol Psychiatry; 2016 Sep; 17(6):467-74. PubMed ID: 26982812
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
Brunero S; Lamont S; Fairbrother G
Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.
Zhang Y; Chen M; Chen J; Wu Z; Yu S; Fang Y; Zhang C
Psychopharmacology (Berl); 2014 May; 231(10):2211-8. PubMed ID: 24448899
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: A study in rural South Indian population.
Rawat VS; Ganesh S; Bijjal S; Shanivaram Reddy K; Agarwal V; Devi R; Kumar CN; Christopher R; Thirthalli J
Schizophr Res; 2018 Feb; 192():102-107. PubMed ID: 28454923
[TBL] [Abstract][Full Text] [Related]
15. Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia.
Yang L; Chen J; Liu D; Yu S; Cong E; Li Y; Wu H; Yue Y; Zuo S; Wang Y; Liang S; Shi Y; Shi S; Xu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():136-41. PubMed ID: 25201120
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Chart Review of Screening on the Prevalence of Metabolic Syndrome (MetS) in an Irish Community Mental Health Service.
Cocoman AM; Gallagher D
Issues Ment Health Nurs; 2019 Oct; 40(10):895-901. PubMed ID: 31295053
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia.
Quek YF; See YM; Yee JY; Rekhi G; Ng BT; Tang C; Lee J
Asian J Psychiatr; 2022 Aug; 74():103192. PubMed ID: 35751958
[TBL] [Abstract][Full Text] [Related]
18. Parental history of diabetes mellitus has additive risk of metabolic syndrome in patients treated with clozapine.
Zeng Y; Chen S; Liu D; Hahn L; Xia X; Wen S; Han Z; Wu X
Asian J Psychiatr; 2020 Apr; 50():101939. PubMed ID: 32087501
[No Abstract] [Full Text] [Related]
19. Cardiovascular disease in patients with schizophrenia.
Kritharides L; Chow V; Lambert TJ
Med J Aust; 2017 Feb; 206(2):91-95. PubMed ID: 28152356
[TBL] [Abstract][Full Text] [Related]
20. The relationship between brain-derived neurotrophic factor and metabolic syndrome in patients with chronic schizophrenia: A systematic review.
Kalejahi P; Kheirouri S; Noorazar SG; Sanayei M
Neuropeptides; 2021 Jun; 87():102135. PubMed ID: 33812160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
